- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05113641
Reducing Dietary Acid With Food Versus Oral Alkali in People With Chronic Kidney Disease (ReDACKD) (ReDACKD)
November 30, 2023 updated by: University of Manitoba
Reducing Dietary Acid With Fruit and Vegetables Versus Oral Alkali in People With Chronic Kidney Disease (ReDACKD) Feasibility Trial
Metabolic acidosis is a common problem that occurs with worsening chronic kidney disease.
Dietary acid can build up when the kidneys are not working well.
This can be associated with a higher risk of worsening kidney function and death.
The usual treatment is a medication called sodium bicarbonate which works to balance the acids in the body.
The medication however often does not work and causes side effects.
Consumption of alkalizing fruit and vegetables may work as a treatment for metabolic acidosis.
This trial is being done to see if fruit and vegetables, provided via home delivery, can become a viable management for metabolic acidosis in patients with chronic kidney disease.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
Metabolic acidosis is a common complication of advanced chronic kidney disease (CKD).
As kidney function declines, the ability to excrete excess dietary acid is reduced.
This can lead to the development of metabolic acidosis, an imbalance in the body's acid-base balance.
Metabolic acidosis is associated with a higher risk of CKD progression and mortality.
Typical treatment includes an oral alkali, such as sodium citrate or sodium bicarbonate.
Recent studies have shown that the treatment of metabolic acidosis can reduce the decline in kidney function and potentially prevent progression of CKD to dialysis.
Treatment rates with an oral alkali are low because the treatments are ineffective, often poorly tolerated, and may be associated with net harm.
Base producing fruit and vegetables are a potential treatment of metabolic acidosis by reducing the dietary contribution to overall acid load that must be managed by the kidneys.
A recent systematic review and meta-analysis of clinical trials using oral alkali supplements or reduction in dietary acid intake using fruits and vegetables, when compared to no treatment, usual care or placebo found that these treatments increased serum bicarbonate and slowed the decline of kidney function.
Fruit and vegetables are an effective and well-tolerated therapy for the treatment of metabolic acidosis in CKD.
While oral alkali therapy has known adverse effects, important limitations also exist in the widespread applicability of fruit and vegetables as a treatment for metabolic acidosis.
Only 2 single center randomized trials have examined the efficacy of fruit and vegetables for the management for acidosis.
This dual-center trial will be the first randomized trial in Canada to evaluate the feasibility of providing fruit and vegetables via home delivery to patients for the management of metabolic acidosis in CKD.
This study will be critical in designing a pan-Canadian phase 3 trial testing the efficacy of alkalizing fruit and vegetable provision on slowing the progression of CKD.
Study Type
Interventional
Enrollment (Estimated)
40
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Rebecca Mollard, PhD
- Phone Number: 204-631-3834
- Email: rmollard@sogh.mb.ca
Study Contact Backup
- Name: Katrina Cachero, MSc, RD
- Phone Number: 204-631-3834
- Email: kcachero@sogh.mb.ca
Study Locations
-
-
Manitoba
-
Winnipeg, Manitoba, Canada, R2V 3M3
- Recruiting
- Seven Oaks General Hospital Chronic Disease Innovation Centre
-
Principal Investigator:
- Dylan Mackay, PhD
-
Sub-Investigator:
- Rebecca Mollard, PhD
-
Contact:
- Navdeep Tangri, MD, PhD
- Phone Number: 204-631-3834
- Email: ntangri@sogh.mb.ca
-
Principal Investigator:
- Navdeep Tangri, MD, PhD
-
Sub-Investigator:
- David Collister, MD
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3H 2Y9
- Not yet recruiting
- Chronic Kidney Disease (Renal) ClinicQEII - Dickson Building
-
Contact:
- Karthik Tennankore, MD
- Phone Number: 902-473-5543
-
Principal Investigator:
- Karthik Tennankore, MD
-
Sub-Investigator:
- Leah Cahill, MD
-
Sub-Investigator:
- Bohdan Lubovyy, PhD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Participant is willing and able to give informed consent for participation in the trial
- Male or Female, aged 18 years or above
- Participants who have an eGFR between 15 and 40 ml/min/1.73m2
- Two consecutive measurements of serum bicarbonate of 14 to 22 mEq/L
- Systolic and diastolic blood pressure <160/100 mmHg
- Serum potassium <5.3 mmol/L
- Hemoglobin A1c below ≤ 11%
- Are registered in the nephrology clinic in Winnipeg or Halifax
- Participants are able to communicate in English and provide written informed consent
Exclusion Criteria:
- Anuria, dialysis or acute kidney injury/acute kidney failure in the 3 months prior to screening
- Chronic obstructive pulmonary disease that requires the participant to be on oxygen
- New York Heart Association Class 3-4 Heart failure symptoms or heart, liver or renal transplant
- A myocardial infarction or stroke within the last 6 months
- Unable to consume study treatments or control, such as swallowing or GI issues
- Participants who have participated in another research trial involving an investigational product in the past 12 weeks
- Currently on potassium binding therapy
- Female participant who is pregnant or on lactating
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Alkalizing Fruit and Vegetables
Participants randomized to fruit and vegetables (F+V) will receive weekly supplementation of alkalizing fruits and vegetables via home delivery in a box format.
Participants will receive a 1-hour dietary counseling session in the first week from a registered dietitian (RD), either in person or via videoconference, depending on regional coronavirus disease (COVID) 19 restrictions and participant preference, which will outline the concepts of the dietary intervention.
The RD will also recommend the best ways to prepare and include the F+V into the participant's current diet.
Intervention will last 12 months.
|
The weekly deliveries will contain combinations of fresh, frozen, and dried fruits and vegetables, as well as juices and soups which have been selected for their negative potential renal acid load (PRAL) values and shelf-life.
All participants will be started at a F+V intake equal to -30 to -40 mEq per day reduction in dietary acid load estimated by the PRAL equation.
Participants serum bicarbonate concentration will be measured at 1 month, and at 3 months, those with values < 22 mEq/L will have their recommended amount of F+V increased to -40 to -50 mEq per day.
If a participant's 1- or 3-month serum bicarbonate value exceeds 29 mEq/L, their target dose of F+V in mEq/d will be reduced by 25%.
|
Active Comparator: Sodium Bicarbonate
Participants randomized to the alkali therapy will receive oral sodium bicarbonate 500mg tablets three times a day, reflecting a common starting dose at clinical practice.
Thereafter, decisions around dose titration for the sodium bicarbonate will then be transferred to the participant's nephrologist who will be responsible for monitoring the participants serum bicarbonate concentration with a goal of maintaining a serum bicarbonate level >22 mEq/L.
Participants will receive counselling from a registered dietician (RD) as part of the standard care.
Intervention will last 12 months.
|
Study nephrologist will prescribe the oral alkali therapy (sodium bicarbonate) and the medications will be dispensed by the Seven Oaks Hospital pharmacy.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Eligibility to randomization ratio
Time Frame: 12 months
|
A ratio of eligibility to randomization expressed as percentage will be collected at 12 months to investigate fruit and vegetable intervention feasibility.
|
12 months
|
Weekly recruitment rate
Time Frame: 12 months
|
Number of new participants per weeks of active recruitment
|
12 months
|
Study outcome follow up
Time Frame: 12 months
|
Study outcome follow up expressed as a percentage, will be calculated at 12 months to investigate the fruit and vegetable intervention feasibility
|
12 months
|
Potential renal acid load (PRAL) in mEq/day
Time Frame: Baseline, 6, and 12 months
|
Calculated from average dietary intake assessed by Automated Self-Administered 24-hour Canada (ASA24) dietary recall survey conducted over three days
|
Baseline, 6, and 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Five repetition chair stand time
Time Frame: Baseline, 3, 6, 9, and 12 months
|
the amount of time it takes for a participant to get up out of a chair five times measured in seconds
|
Baseline, 3, 6, 9, and 12 months
|
Physical function related quality of life
Time Frame: Baseline, 3, 6, 9, and 12 months
|
Participants will complete the SF-12 physical component score of the Kidney Disease Quality of Life Short Form (KDQOL-SF) questionnaire.
The questionnaire is scored between 0-100 with higher values representing physical function related quality of life.
|
Baseline, 3, 6, 9, and 12 months
|
Serum bicarbonate (total CO2)
Time Frame: Baseline, 1, 3, 6, 9, and 12 month(s)
|
Serum bicarbonate concentration in milliequivalents per liter (mEq/L)
|
Baseline, 1, 3, 6, 9, and 12 month(s)
|
Albumin
Time Frame: Baseline, 1, 3, 6, 9, and 12 month(s)
|
blood albumin is measured in grams per deciliter (g/dL)
|
Baseline, 1, 3, 6, 9, and 12 month(s)
|
Calcium
Time Frame: Baseline, 1, 3, 6, 9, and 12 month(s)
|
Total blood calcium concentration in mmol/L
|
Baseline, 1, 3, 6, 9, and 12 month(s)
|
Estimated Glomerular Filtration Rate (eGFR)
Time Frame: Baseline, 1, 3, 6, 9, and 12 month(s)
|
calculated from serum creatinine, sex, and age, reported in mL/min/1.73
m2
|
Baseline, 1, 3, 6, 9, and 12 month(s)
|
Glucose
Time Frame: Baseline, 1, 3, 6, 9, and 12 month(s)
|
Total blood glucose concentration in mmol/L
|
Baseline, 1, 3, 6, 9, and 12 month(s)
|
Potassium
Time Frame: Baseline, 1, 3, 6, 9, and 12 month(s)
|
The total blood potassium concentration in mmol/L
|
Baseline, 1, 3, 6, 9, and 12 month(s)
|
Chloride
Time Frame: Baseline, 1, 3, 6, 9, and 12 month(s)
|
Total blood chloride concentration in mmol/L
|
Baseline, 1, 3, 6, 9, and 12 month(s)
|
Sodium
Time Frame: Baseline, 1, 3, 6, 9, and 12 month(s)
|
The total sodium concentration in mmol/L
|
Baseline, 1, 3, 6, 9, and 12 month(s)
|
Phosphorus
Time Frame: Baseline, 1, 3, 6, 9, and 12 month(s)
|
The total blood phosphorus concentration in mmol/L
|
Baseline, 1, 3, 6, 9, and 12 month(s)
|
Hemoglobin A1c
Time Frame: Baseline, 1, 3, 6, 9, and 12 month(s)
|
Hemoglobin A1c in percentage
|
Baseline, 1, 3, 6, 9, and 12 month(s)
|
Blood Urea Nitrogen (BUN)
Time Frame: Baseline, 1, 3, 6, 9, and 12 month(s)
|
Blood Urea Nitrogen (BUN) is reported in millimole per litre (mmol/L)
|
Baseline, 1, 3, 6, 9, and 12 month(s)
|
Urine Albumin/Creatinine Ratio
Time Frame: Baseline, 1, 3, 6, 9, and 12 month(s)
|
The ratio of albumin to creatinine concentrations in urine, reported in Milligrams albumin per millimole creatinine
|
Baseline, 1, 3, 6, 9, and 12 month(s)
|
Systolic blood pressure in mmHg
Time Frame: Baseline, 1, 3, 6, 9, and 12 months
|
Blood pressure will be measured in triplicate using a validated blood pressure monitor following Kidney Disease: Improving Global Outcomes (KDIGO) 2021 measurement guidelines, the average of the 2nd and 3rd measurements will be recorded.
|
Baseline, 1, 3, 6, 9, and 12 months
|
Diastolic blood pressure in mmHg
Time Frame: Baseline, 1, 3, 6, 9, and 12 months
|
Blood pressure will be measured in triplicate using a validated blood pressure monitor following KDIGO 2021 measurement guidelines, the average of the 2nd and 3rd measurements will be recorded.
|
Baseline, 1, 3, 6, 9, and 12 months
|
Edmonton Symptom Assessment System (ESAS) - Revised Renal
Time Frame: Baseline, 3, 6, 9, and 12 months
|
A questionnaire used to rate the intensity of nine common symptoms experienced by renal patients, including pain, tiredness, drowsiness, nausea, appetite levels, shortness of breath, depression and anxiety levels, and well-being.
Minimum value 0 and maximum value 100 with higher values being worse.
|
Baseline, 3, 6, 9, and 12 months
|
All cause hospitalization
Time Frame: 3, 6, 9, and 12 months
|
Information on recent hospitalizations from participant's clinical records will be collected.
|
3, 6, 9, and 12 months
|
All cause mortality
Time Frame: 3, 6, 9, 12 months
|
Information on mortality from participant's clinical records will be collected.
|
3, 6, 9, 12 months
|
Changes in medication
Time Frame: Baseline,1, 3, 6, 9, and 12 months
|
Research coordinator will update information on concomitant medications or supplements information with the participant
|
Baseline,1, 3, 6, 9, and 12 months
|
Height
Time Frame: Baseline, 3, 6, 9, and 12 months
|
Height will be measured using a validated stadiometer in centimeters..
|
Baseline, 3, 6, 9, and 12 months
|
Weight
Time Frame: Baseline, 3, 6, 9, and 12 months
|
Weight will be measured using a calibrated scale in kilograms.
|
Baseline, 3, 6, 9, and 12 months
|
Body Mass Index (BMI)
Time Frame: Baseline, 3, 6, 9, and 12 months
|
MBI will be calculated through dividing weight in kilograms (kg) by the square of height in meters (m2).
|
Baseline, 3, 6, 9, and 12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Navdeep Tangri, MD, PhD, Seven Oaks General Hospital Chronic Disease Innovation Centre
- Principal Investigator: Dylan MacKay, PhD, George and Fay Yee Centre for Healthcare Innovation
- Principal Investigator: Karthik Tennankore, MD, Nova Scotia Health Authority
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
December 1, 2023
Primary Completion (Estimated)
December 1, 2024
Study Completion (Estimated)
February 1, 2025
Study Registration Dates
First Submitted
October 15, 2021
First Submitted That Met QC Criteria
October 28, 2021
First Posted (Actual)
November 9, 2021
Study Record Updates
Last Update Posted (Actual)
December 1, 2023
Last Update Submitted That Met QC Criteria
November 30, 2023
Last Verified
January 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Metabolic Diseases
- Urologic Diseases
- Disease Attributes
- Renal Insufficiency
- Acid-Base Imbalance
- Chronic Disease
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Kidney Diseases
- Renal Insufficiency, Chronic
- Acidosis
Other Study ID Numbers
- HS24768 (B2021:025)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Kidney Diseases
-
3-C Institute for Social DevelopmentUniversity of North Carolina, Chapel HillCompletedChronic Kidney Diseases | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage4 | Pediatric Kidney Disease | Chronic Kidney Disease stage3 | Chronic Kidney Disease Stage V | Chronic Kidney Disease, Stage IV (Severe) | Chronic Kidney Disease Stage 2 | Chronic Kidney Disease, Stage IUnited States
-
American Academy of Family PhysiciansUniversity of Colorado, Denver; National Institute of Diabetes and Digestive... and other collaboratorsCompletedChronic Kidney Disease | Chronic Renal Insufficiency | Chronic Kidney Insufficiency | Chronic Renal Diseases | Kidney Insufficiency, ChronicUnited States
-
Universiti Putra MalaysiaRecruitingChronic Kidney Diseases | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage4 | Chronic Kidney Disease stage3 | Chronic Kidney Disease Requiring Chronic DialysisMalaysia
-
Centre Hospitalier le MansLe Mans UniversiteWithdrawnFatigue | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage3 | Chronic Kidney Failure | Chronic Kidney Disease, Stage 4 (Severe)
-
National Taiwan University HospitalCompletedChronic Kidney Disease stage4 | Chronic Kidney Disease stage3 | Chronic Kidney Disease Stage 2 | Chronic Kidney Disease Stage 1Taiwan
-
Centre Hospitalier le MansLe Mans UniversiteRecruitingFatigue | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage4 | Chronic Kidney Disease Stage 3BFrance
-
University of WashingtonJohns Hopkins University; National Institute of Diabetes and Digestive and... and other collaboratorsRecruitingChronic Kidney Diseases | Acute Renal Failure | Acute Renal Injury | Acute Kidney Failure | Chronic Renal Insufficiency | Kidney Failure, Acute | Renal Insufficiency, Acute | Acute Renal Insufficiency | Acute Kidney Insufficiency | Renal Failure, Acute | Chronic Kidney Insufficiency | Chronic Renal Diseases | Kidney... and other conditionsUnited States
-
University of the State of Santa CatarinaUnknownKidney Diseases | Chronic Kidney Diseases | Hemodialysis | Chronic Renal Insufficiency | Renal Dialysis | Chronic Kidney Insufficiency | Chronic Renal DiseasesBrazil
-
Texas A&M UniversityWithdrawnChronic Kidney FailureUnited States
-
Lund UniversityBaxter Healthcare Corporation; Universidad de CórdobaCompletedEnd Stage Kidney Disease | Chronic Kidney Disease Requiring Chronic DialysisArgentina
Clinical Trials on Alkalizing Fruit and Vegetables
-
Queen's University, BelfastCompletedChronic Obstructive Pulmonary DiseaseUnited Kingdom
-
Queen's University, BelfastCompletedHealthyUnited Kingdom
-
University Hospital Southampton NHS Foundation...Medical Research Council; University of Southampton; National Institute for Health... and other collaboratorsActive, not recruitingDiet ModificationUnited Kingdom
-
King Abdulaziz UniversityCompletedFruit and Vegetable IntakeSaudi Arabia
-
Queen's University, BelfastBelfast Health and Social Care TrustCompletedHypertensionUnited Kingdom
-
Wholesome WaveYale-Griffin Prevention Research Center; One Community HealthCompletedDiabetes Mellitus, Type 2 | Diabetes Mellitus | PovertyUnited States
-
PepsiCo Global R&DCompletedGlycemic IndexUnited States
-
Baylor Research InstituteCompletedCardiovascular Diseases | Hypertension | Chronic Kidney DiseasesUnited States
-
Karolinska InstitutetKarolinska University HospitalCompletedHypertension | Cardiovascular DiseaseSweden
-
The University of Tennessee, KnoxvilleActive, not recruitingObesityUnited States